Logo image of HNGE

HINGE HEALTH INC-A (HNGE) Stock Fundamental Analysis

USA - NYSE:HNGE - US4333131039 - Common Stock

50.74 USD
+0.33 (+0.65%)
Last: 10/16/2025, 8:04:01 PM
50.01 USD
-0.73 (-1.44%)
After Hours: 10/16/2025, 8:04:01 PM
Fundamental Rating

4

Taking everything into account, HNGE scores 4 out of 10 in our fundamental rating. HNGE was compared to 100 industry peers in the Health Care Providers & Services industry. While HNGE has a great health rating, there are worries on its profitability. While showing a medium growth rate, HNGE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HNGE had negative earnings in the past year.
HNGE Yearly Net Income VS EBIT VS OCF VS FCFHNGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 -50M -100M

1.2 Ratios

HNGE has a Return On Assets (-1.72%) which is in line with its industry peers.
HNGE has a Return On Equity (-3.19%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -1.72%
ROE -3.19%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HNGE Yearly ROA, ROE, ROICHNGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

HNGE has a Gross Margin of 77.00%. This is amongst the best in the industry. HNGE outperforms 92.00% of its industry peers.
The Profit Margin and Operating Margin are not available for HNGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HNGE Yearly Profit, Operating, Gross MarginsHNGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 20 -20 40 -40 60

More info and screens

7

2. Health

2.1 Basic Checks

HNGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HNGE remains at a similar level compared to 1 year ago.
There is no outstanding debt for HNGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HNGE Yearly Shares OutstandingHNGE Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
HNGE Yearly Total Debt VS Total AssetsHNGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200M 400M 600M

2.2 Solvency

HNGE has an Altman-Z score of 6.17. This indicates that HNGE is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.17, HNGE belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.
There is no outstanding debt for HNGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.17
ROIC/WACCN/A
WACC8.69%
HNGE Yearly LT Debt VS Equity VS FCFHNGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

HNGE has a Current Ratio of 1.91. This is a normal value and indicates that HNGE is financially healthy and should not expect problems in meeting its short term obligations.
HNGE has a better Current ratio (1.91) than 72.00% of its industry peers.
HNGE has a Quick Ratio of 1.86. This is a normal value and indicates that HNGE is financially healthy and should not expect problems in meeting its short term obligations.
HNGE has a better Quick ratio (1.86) than 73.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.86
HNGE Yearly Current Assets VS Current LiabilitesHNGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

HNGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.96%, which is quite impressive.
The Revenue has grown by 33.37% in the past year. This is a very strong growth!
EPS 1Y (TTM)88.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)33.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 125.93% on average over the next years. This is a very strong growth
Based on estimates for the next years, HNGE will show a very strong growth in Revenue. The Revenue will grow by 26.43% on average per year.
EPS Next Y488.89%
EPS Next 2Y210.48%
EPS Next 3Y125.93%
EPS Next 5YN/A
Revenue Next Year43.83%
Revenue Next 2Y31.32%
Revenue Next 3Y26.43%
Revenue Next 5YN/A

3.3 Evolution

HNGE Yearly Revenue VS EstimatesHNGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 200M 400M 600M
HNGE Yearly EPS VS EstimatesHNGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.5 1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

HNGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 43.41, the valuation of HNGE can be described as expensive.
HNGE's Price/Forward Earnings is on the same level as the industry average.
HNGE is valuated expensively when we compare the Price/Forward Earnings ratio to 22.85, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 43.41
HNGE Price Earnings VS Forward Price EarningsHNGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HNGE Per share dataHNGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

HNGE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HNGE's earnings are expected to grow with 125.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y210.48%
EPS Next 3Y125.93%

More info and screens

0

5. Dividend

5.1 Amount

HNGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HINGE HEALTH INC-A

NYSE:HNGE (10/16/2025, 8:04:01 PM)

After market: 50.01 -0.73 (-1.44%)

50.74

+0.33 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04
Inst Owners127.07%
Inst Owner Change0.03%
Ins Owners8.08%
Ins Owner Change-1528.14%
Market Cap3.98B
Analysts82.86
Price Target64.62 (27.36%)
Short Float %7.75%
Short Ratio1.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.69%
PT rev (3m)36.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)142.97%
EPS NY rev (1m)-42.69%
EPS NY rev (3m)-9.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.41
P/S 10.19
P/FCF N/A
P/OCF N/A
P/B 10.65
P/tB 12.98
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)1.17
Fwd EY2.3%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.98
BVpS4.76
TBVpS3.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.72%
ROE -3.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 1.86
Altman-Z 6.17
F-ScoreN/A
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y488.89%
EPS Next 2Y210.48%
EPS Next 3Y125.93%
EPS Next 5YN/A
Revenue 1Y (TTM)33.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year43.83%
Revenue Next 2Y31.32%
Revenue Next 3Y26.43%
Revenue Next 5YN/A
EBIT growth 1Y81.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year436.28%
EBIT Next 3Y99.9%
EBIT Next 5YN/A
FCF growth 1Y166.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y176.68%
OCF growth 3YN/A
OCF growth 5YN/A